Inflammatory systemic biomarkers in setting acute coronary syndromes - Effects of the diurnal variation

Current Drug Targets

Volumn 10, Issue 10, 2009, Pages 1001-1008

  Dominguez Rodriguez, A ^a   Abreu Gonzalez, P ^b   Kaski, J C ^c  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

^c ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Acute coronary syndromes; Biomarkers; Circadian rhythm; Diurnal variation; Inflammation; Preanalytical variations

Indexed keywords

ABCIXIMAB; AUTACOID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CD40 LIGAND; COLLAGENASE 3; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MELATONIN; NEOPTERIN; NEUTROPHIL COLLAGENASE; STROMELYSIN; STROMELYSIN 2; STROMELYSIN 3; VASCULAR CELL ADHESION MOLECULE 1;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BLOOD SAMPLING; BLOOD VESSEL WALL; CARDIOVASCULAR RISK; CIRCADIAN RHYTHM; CLINICAL ASSESSMENT; CORONARY ARTERY DISEASE; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOSTIMULATION; INFLAMMATION; LYMPHOCYTE COUNT; NEUTROPHIL COUNT; PATIENT CARE; PROGNOSIS; REVIEW; RISK ASSESSMENT; T LYMPHOCYTE; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; ANIMALS; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; CIRCADIAN RHYTHM; HUMANS; INFLAMMATION MEDIATORS; PROGNOSIS;

EID: 70450205127     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009789577963     Document Type: Review

References (118)

1. Hansson GK. Mechanisms of disease inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695
2. Ross R. Atherosclerosis- an inflammatory disease. N Engl J Med 1999; 340: 115-126
3. Libby P. Inflammation in atherosclerosis. Nature 200; 420: 868-874
4. Schroeder AP, Falk E. Pathophysiology and inflammatory aspects of plaque rupture. Cardiol Clin 1996; 14: 211-220 (Pubitemid 26153994)
5. Fichtlscherer S, Heeschen C, Zeiher AM. Inflammatory markers and coronary artery disease. Curr Opin Pharmacol 2004; 4: 124-131 (Pubitemid 38444046)
6. Muller JE, Tofler GH. Circadian variation and cardiovascular disease. N Engl J Med 1991; 325: 1038-1039
7. Willich SN, Goldberg RJ, Maclure M, Perriello L, Muller JE. Increased onset of sudden cardiac death in the first three hours after awakening. Am J Cardiol 1992; 70: 65-68
8. Reilly DF, Westgate EJ, FitzGerald GA. Peripheral circadian clocks in the vasculature. Arterioscler Thromb Vasc Biol 2007; 27: 1694-1705
9. Rajaratnam SM, Arendt J. Health in a 24-h society. Lancet 2001; 358: 999-1005.
10. Knutsson A. Health disorders of shift workers. Occup Med (Lond) 2003; 53: 103-108
11. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscler Thromb Vasc Biol 2007; 27: 15-26. (Pubitemid 46360377)
12. Rudnicka AR, Rumley A, Lowe GD, Strachan DP. Diurnal, seasonal, and blood-processing patterns in levels of circulating fibrinogen, fibrin D-dimer, C-reactive protein, tissue plasminogen activator, and von Willebrand factor in a 45-year-old population. Circulation 2007; 115: 996-1003. (Pubitemid 46328293)
13. Atkinson AJ, Colburn WA, De Gruttola VG, De Mets DL, Downing GJ, Hoth DF, et al. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69: 89-95.
14. Morrow DA. Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation 2003; 108: 250-252 (Pubitemid 36899010)
15. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation 2007; 115: 949-952
16. Rai AJ, Vitzthum F. Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics. Expert Rev Proteom 2006; 3: 409-426 (Pubitemid 44231984)
17. Vasan R. Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation 2006; 113: 2335-2362 (Pubitemid 43947980)
18. Petersen PH, Ricos C, Stockl D, Libeer JC, Baadenhuijsen H, Fraser C, et al. Proposed guidelines for the internal quality control of analytical results in the medical laboratory. Eur J Clin Chem Clin Biochem 1996; 34: 983-999
19. Fraser CG, Hyltoft Petersen P. Analytical performance characteristics should be judged against objective quality specifications. Clin Chem 1999; 45: 321-323
20. Sebastian-Gambaro MA, Liron-Hernandez FJ, Fuentes-Arderiu X. Intra- and inter-individual biological variability data bank. Eur J Clin Chem Clin Biochem 1997; 35: 845-852 (Pubitemid 27510862)
21. Guder WG. Preanalytical factors and their influence or analytical duality specifications. Scand J Clin Lab Invest 1999; 59: 545-549 (Pubitemid 30056749)
22. Harris EK, Yasaka T, Horton MR, Shakarji G. Comparing multivariate and univariate subject-specific reference regions for blood constituents in healthy persons. Clin Chem 1982; 28: 422-426
23. Harris EK, Yasaka T. On the calculation of a reference change for comparing two consecutive measurements. Clin Chem 1983; 29: 25-30. (Pubitemid 13167613)
24. Queraltó JM, Boyd JC, Harris EK. On the calculation of reference change values with examples from a long-term study. Clin Chem 1993; 39: 1398-1403 (Pubitemid 23215323)
25. Rattazzi M, Puato M, Faggin E, Bertipaglia B, Zambon A, Pauletto P. C-reactive protein and interleukin-6 in vascular disease: culprits or passive bystanders? J Hypertens 2003; 21: 1787-1803.
26. Kerr R, Stirling D, Ludlam CA. Interleukin 6 and haemostasis. Br J Haematol 2001; 115: 3-12.
27. Seino Y, Ikeda U, Ikeda M, Yamamoto K, Misawa Y, Hasegawa T, et al. Interleukin 6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 1994; 6: 87-91. (Pubitemid 24120205)
28. Rus HG, Vlaicu R, Niculescu F. Interleukin-6 and inteleukin-8 protein and gene expression in human arterial atherosclerotic wall. Atherosclerosis 1996; 127: 263-271. (Pubitemid 27045840)
29. Schieffer B, Schieffer E, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, et al. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 2000; 101: 1372-1378 (Pubitemid 30169857)
30. Biasucci LM, Liuzzo G, Fantuzzi G, Caligiuri G, Rebuzzi AG, Ginnetti F, et al. Increasing levels of interleukin (IL)-1 Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999; 99: 2079-2084 (Pubitemid 29196789)
31. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. J Am Med Assoc 2001; 286: 2107-2113 (Pubitemid 34041595)
32. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101: 1767-1772 (Pubitemid 30213096)
33. Pradhan AD, Manson JE, Rossouw JE, Siscovick DS, Mouton CP, Rifai N, et al. Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observation study. J Am Med Assoc 2002; 288: 980-987 (Pubitemid 34920463)
34. Harris TB, Ferruci L, Tracy RP, Corti MC, Wacholder S, Ettinger WH Jr, et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am J Med 1999; 106: 506-512 (Pubitemid 29231100)
35. Volpato S, Guralnik JM, Ferruci L, Balfour J, Chaves P, Fried LP, et al. Cardiovascular disease, interleukin-6, and risk of mortality in older women's health and aging study. Circulation 2001; 103: 947-953 (Pubitemid 32183799)
36. Abo T, Kawate K, Itoh K, Kumagai K. Studies on the bioperiodicity of the immune response. Circadian rhythms of human T, B and K cell trafic in the peripheral blood. J Immunol 1981; 126: 1360-1366 (Pubitemid 11149225)
37. Ancey C, Corbi P, Froger J, Delwail A, Wijdenes J, Gascan H, et al. Secretion of IL-6, IL-11 and LIF by human cardiomyocytes in primary culture. Cytokine 2002; 18: 199-205. (Pubitemid 34775428)
38. Jankovic BD. Neuroimmunomodulation. From phenomenology to molecular evidence. Ann N Y Acad Sci 1994; 741: 1-38.
39. Maestroni GJM, Conti A, Pierpaoli W. Pineal melatonin, its fundamental immunoregulatory role in aging and cancer. Ann N Y Acad Sci 1988; 521: 140-148 (Pubitemid 18229222)
40. Guerrero JM, Reiter RJ. Melatonin-immune system relationship. Curr Top Med Chem 2002; 2: 167-179
41. Sothern RB, Roitman-Johnson B, Kanabrocki EL, Yager JG, Roodel MM, Weatherbee JA, et al. Circadian characteristics of circulating IL-6 in men. J Allergy Clin Immunol 1995; 95: 1029-1035
42. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia MJ, de la Rosa A, Vargas M, Marrero F. Circadian variations in proinflammatory cytokine concentrations in acute myocardial infarction. Rev Esp Cardiol 2003; 56: 555-560 (Pubitemid 36896685)
43. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia M, Ferrer J, de la Rosa A, Vargas M, et al. Light/dark patterns of interleukin-6 in relation to the pineal hormone melatonin in patients with acute myocardial infarction. Cytokine 2004; 26: 89-93. (Pubitemid 38410888)
44. Auerbach G, Nar H. The pathway from GTP to tetrahydrobiopterin: three-dimensional structures of GTP cyclohydroxilase I and 6-pyruvoyl tetrahydropterin synthase. Biol Chem 1997; 378: 185-192 (Pubitemid 27230601)
45. Huber C, Batchelor JR, Fuchs D, Hausen A, Lang A, Niederwieser D, et al. Immune response-assoaciated production of neopterin. Release from macrophages primarily under control of interferongamma. J Exp Med 1984; 160: 310-316 (Pubitemid 14089799)
46. Avanzas P, Arroyo-Espliguero R, Cosin-Sales J, Aldama G, Pizzi C, Quiles J, et al. Markers of inflammation and multiple complex stenoses (pancoronary plaque vulnerability) in patients with non-ST segment elevation acute coronary syndromes. Heart 2004; 90: 847-852 (Pubitemid 39022574)
47. van Haelst PL, Liem A, van Boven AJ, Veeger NJ, van Veldhuisen DJ, Tervaert JW, et al. Usefulness of elevated neopterin and C-reactive protein levels in predicting cardiovascular events in patients with non-Q-wave myocardial infarction. Am J Cardiol 2003; 92: 1201-1203 (Pubitemid 37377833)
48. Zouridakis E, Avanzas P, Arroyo-Espliguero R, Fredericks S, Kaski JC. Markers of inflammation and rapid coronary artery disease progresión in patients with stable angina pectoris. Circulation 2004; 110: 1747-1753 (Pubitemid 39299216)
49. Avanzas P, Arroyo-Espliguero R, Quiles J, Roy D, Kaski JC. Elevated serum neopterin predicts future adverse cardiac events in patients with chronic stable angina pectoris. Eur Heart J 2005; 26: 457-463 (Pubitemid 40314761)
50. Garcia-Moll X, Cole D, Zouridakis E, Kaski JC. Increased serum neopterin: a marker of coronary artery disease activity in women. Heart 2000; 83: 346-350 (Pubitemid 30313342)
51. Avanzas P, Arroyo-Espliguero R, Cosin-Sales J, Quiles J, Zouridakis E, Kaski JC. Prognostic value of neopterin levels in treated patients with hipertensión and chest pain but without obstructive coronary artery disease. Am J Cardiol 2004; 93: 627-629 (Pubitemid 38293075)
52. Kaski JC, Cruz-Fernandez JM, Fernandez-Berges D, Garcia-Moll X, Martin JL, Mostaza J, et al. [Inflammation markers and risk stratification in patients with acute coronary syndromes: design of the SIESTA Study (Systemic Inflammation Evaluation in Patients with non-ST segment elevation Acute coronary syndromes)]. Rev Esp Cardiol 2003; 56: 389-395 (Pubitemid 36608979)
53. Kaski JC, Consuegra-Sanchez L, Fernandez-Berges DJ, Cruz-Fernandez JM, Garcia-Moll X, Marrugat J, et al. Elevated serum neopterin levels and adverse cardiac events at 6 months follow-up in Mediterranean patients with non-ST-segment elevation acute coronary syndrome. Atherosclerosis 2008 [Epub ahead of print]
54. Kaski JC, Avanzas P, Arroyo-Espliguero R. Neopterin: still a forgotten biomarker. Clin Chem 2005; 51: 1902-1903
55. Libby P. Current concepts of the pathogenesis of acute coronary syndromes. Circulation 2001; 104: 365-369 (Pubitemid 32666962)
56. Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, Frye RL, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation 2000; 101: 2883-2888 (Pubitemid 30415876)
57. Methe H, Brunner S, Wiegand D, Nabauer M, Koglin J, Edelman ET. Enhanced T-helper-1 lymphocyte activation patterns in acute coronary syndromes. J Am Coll Cardiol 2005; 45: 1939-1945 (Pubitemid 40814112)
58. Petrovsky N, Harrison LC. The chronobiology of human cytokine production. Int Rev Immunol 1998; 16: 635-649.
59. Born J, Lange T, Hansen K, Molle M, Fehm HL. Effects of sleep and circadian rhythm on human circulating immune cells. J Immunol 1997; 158: 4454-4464 (Pubitemid 127483950)
60. Auzéby A, Bogdan A, Krosi Z, Touitou Y. Time-dependence of urinary neopterin, a marker of cellular immune activity. Clin Chem 1988; 34: 1866-1867 (Pubitemid 18235422)
61. Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Abreu-Gonzalez P. Diurnal variations in serum neopterin levels are associated with the pineal hormone melatonin circadian rhythm in healthy human subjects. J Pineal Res 2006; 40: 288-289 (Pubitemid 43344664)
62. Levi FA, Canon C, Touitou Y, Sulon J, Mechkouri M, Ponsart ED, et al. Circadian rhythms in circulating T lymphocyte subtypes and plasma testosterone, total and free cortisol in five healthy men. Clin Exp Immunol 1988; 71: 329-335 (Pubitemid 18065790)
63. Garcia-Gonzalez MJ, Dominguez-Rodriguez A, Abreu-Gonzalez P. Light/dark variations in neopterin serum levels in patients with ST-segment elevation acute coronary syndrome undergoing primary angioplasty. Rev Esp Cardiol 2008; 61: 1280-1286
64. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-262
65. Mach F. The role of chemokines in atherosclerosis. Curr Atheroscler Rep 2001; 3: 243-251
66. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503 (Pubitemid 24379627)
67. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K. Plasma levels of matriz metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary síndrome. Am Heart J 2001;141: 211-217 (Pubitemid 32128725)
68. Kai H, Ikeda H, Yasukawa H, Kai M, Seki Y, Kuwahara F, et al. Peripheral blood levels of matrix metalloproteinases-2 and -9 are elevated in patients with acute coronary syndromes. J Am Coll Cardiol 1998; 32: 368-372. (Pubitemid 28396484)
69. Eckart RE, Uyehara CF, Shry EA, Furgerson JL, Krasuski RA. Matrix metalloproteinases in patients with myocardial infarction and percutaneous revascularization. J Interv Cardiol 2004; 17: 27-31. (Pubitemid 38326510)
70. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, et al. AtheroGene Investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107: 1579-1585
71. Ferroni P, Basili S, Martini F, Cardarello CM, Ceci F, di Franco M, et al. Serum metalloproteinase 9 levels in patients with coronary artery disease: a novel marker of inflammation. J Invest Med 2003; 51: 295-300.
72. Jones CB, Sane DC, Herrington DM. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003; 59: 812-823
73. Tayebjee MH, Lip GY, Blann AD. MacFadyen RJ. Effects of age, gender, ethnicity, diurnal variation and exercise on circulating levels of matrix metalloproteinases (MMP)-2 and -9, and their inhibitors, tissue inhibitors of matrix metalloproteinases (TIMP)-1 and - 2. Thromb Res 2005; 115: 205-210
74. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Reiter RJ. Relation of nocturnal melatonin levels to serum matriz metalloproteinase-9 concentrations in patients with myocardial infarction. Thromb Res 2007; 120: 361-366
75. Dominguez-Rodriguez A, Kaski JC, Abreu-Gonzalez P, Garcia-Gonzalez MJ. The kinetics of metalloproteinase-9: the significance of the light-dark cycle in metalloproteinase-9 in acute coronary syndrome. Res Esp Cardiol 2008; 61: 327.
76. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-314.
77. Albelde SM, Oliver PD, Romer LH, Buck CA. EndoCAM: a novel endothelial cell-cell adhesion molecule. J Cell Biol 1990; 110: 1227-1237
78. Newman PJ, Berdnt MC, Gorsky J, White GC, Paddock LS, Muller WA. PECAM-1(CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science 1990; 247: 1219-1222
79. Davies MJ, Gordon JL, Gearing AJ, Pigott R, Woolf N, Katz D, et al. The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis. J Pathol 1993; 171: 223-229 (Pubitemid 23345967)
80. Elices M, Osborn L, Takada Y, Crouse C, Luhowskj S, Hemler M, et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990; 60: 577-584 (Pubitemid 20083814)
81. Niessen H, Krijnen P, Visser C, Meijer C, Hack C. Intercellular adhesion molecule-1 in the heart. Ann NY Acad Sci 2002; 973: 573-585
82. Rallidis L, Gika H, Zolindaki M, Xydas T, Paravolidakis K, Velissaridou A. Usefulness of elevated levels of soluble vascular cell adhesion molecule-1 in predicting in-hospital prognosis in patients with unstable angina pectoris. Am J Cardiol 2003; 92: 1195-1197 (Pubitemid 37377831)
83. Mulvihill N, Foley J, Murphy R, Curtin R, Crean P, Walsh M. Risk stratification in unstable angina and non-Q wave myocardial infarction using soluble cell adhesion molecules. Heart 2001; 85: 623-627 (Pubitemid 32973454)
84. Armstrong EJ, Morrow DA, Sabatine MS. Inflammatory biomarkers in acute coronary syndromes. Part II: acute-phase reactants and biomarkers of endothelial cell activation. Circulation 2006; 113: e152-5.
85. Mulvihill N, Foley J, Murphy R, Crean P, Walsh M. Evidence of prolonged inflammation in unstable angina and non-Q wave myocardial infarction. J Am Coll Cardiol 2000; 36: 1210-1216 (Pubitemid 30760584)
86. Luc G, Arveiler D, Evans A, Amouyel P, Ferrieres J, Bard JM, et al; PRIME Study Group. Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: the PRIME Study. Atherosclerosis 2003; 170: 169-176
87. Maple C, Kirk G, Mclaren M, Veale D, Belch JJ. A circadian variation exists for soluble levels of intercellular adhesion molecule- 1 and E-selectin in healthy volunteers. Clin Sci 1998; 94: 537-540 (Pubitemid 28205920)
88. Mosevold KA, Bruserud O. Circadian variation do not have a major impacto n serum levels of soluble (s) L-selectin (CD63L), s-intercellular adhesion molecule 1 (sICAM-1/CD54) and thrombopoietin in healthy individuals. Scand J Clin Lab Invest 2002; 62: 75-79 (Pubitemid 34185038)
89. Osmancik P, Kvasnicka J, Widimsky P, Tarnok A. Diurnal variation of soluble E- and P-selectin, and intercellular adhesion molecule-1 in patients with and without coronary artery disease. Cardiology 2004; 102: 194-199 (Pubitemid 39370533)
90. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Samimi-Fard S, Kaski JC, Reiter RJ. Light/dark patterns of soluble vascular cell adhesion molecule-1 in relation to melatonin in patients with ST-segment elevation myocardial infarction. J Pineal Res 2008; 44: 65-69 (Pubitemid 350231111)
91. Schonbeck U, Libby P. The CD40/CDE154 receptor/ligand dyad. Cell Moll Life Sci 2001; 58: 4-43.
92. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67: 2-17.
93. Henn V, Steinbach S, Buchner P, Presek P, Kroczek RA. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 2001; 15: 1047-1054
94. Schonbeck U, Libby P. CD40 signaling and plaque instability. Circ Res 2001; 89: 1092-1103
95. Blake GJ, Ostfeld RJ, Yucel EK, Varo N, Schonbeck U, Blake MA, et al. Soluble CD40 ligand levels indicate lipid accumulation in carotid atheroma: an in vivo study with high-resolution MRI. Arterioscler, Thromb Vasc Biol 2003; 23: e11-e4.
96. Heeschen C, Dimmeler S, Hamm CW, van den Brand MJ, Boersma E, Zeiher AM, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 2003; 348: 1104-1111 (Pubitemid 36337321)
97. Kinlay S, Schwartz GG, Olsson AG, Rifai N, Sasiela WJ, Szarek M, et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation 2004; 110: 386-391
98. Varo N, de Lemos JA, Libby P, Morrow DA, Murphy SA, Unzo R, et al. Soluble CD40L: risk prediction after acute coronary síndromes. Circulation 2003; 108: 1049-1052 (Pubitemid 37071512)
99. Malarstig A, Lindahl B, Wallentin L, Siegbahn A. Soluble CD40L levels are regulated by the -3459 A > G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome. Arterioscler Thromb Vasc Biol 2006; 26: 1667-1673
100. Conde ID, Kleiman NS. Soluble CD40 ligand in acute coronary syndromes [Letter]. N Engl J Med 2003; 348: 2575-2577 (Pubitemid 36706547)
101. Ahn ER, Lander G, Jy W, Bidot CJ, Jimenez JJ, Horstman LL, et al. Differences of soluble CD40L in sera and plasma: implications on CD40L assay as a marker of thrombotic risk. Thromb Res 2004; 114: 143-148 (Pubitemid 39078587)
102. Weber M, Rabenau B, Stanisch M, Elsaesser A, Mitrovic V, Heeschen C, et al. Influence of sample type and storage conditions on soluble CD40 ligand assessment. Clin Chem 2006; 52: 888-891 (Pubitemid 43673269)
103. Halldorsdottir AM, Stroker J, Porche-Sorbet R, Eby CS. Soluble CD40 ligand measurement inaccuracies attributable to specimen type, processing time, and ELISA method. Clin Chem 2005; 51: 1054-1057 (Pubitemid 40740898)
104. Ivandic BT, Spanuth E, Haase D, Lestin HG, Katus HA. Increased plasma concentrations of soluble CD40 ligand in acute coronary syndrome depend on in vitro platelet activation. Clin Chem 2007; 53: 1231-1234
105. Dominguez-Rodriguez A, Abreu-Gonzalez P, Garcia-Gonzalez MJ, Kaski JC. Diurnal variation of soluble CD40 ligand in patients with acute coronary síndrome. Soluble CD40 ligand and diurnal variation. Thromb Res 2009; 123: 617-621
106. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol 2006; 48: 1-11. (Pubitemid 44202476)
107. Dominguez-Rodriguez A, Abreu-Gonzalez P. Light-dark patterns of soluble CD40 ligand: Clinical implications. Am Heart J 2009; 157: e3.
108. Kushner I, Broder ML, Karp D. Control of the acute phase response. Serum C-reactive protein kinetics after acute myocardial infarction. J Clin Invest 1978; 61: 235-242 (Pubitemid 8280392)
109. Calabro P, Willerson JT, Yeh ET. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003; 108: 1930-1932 (Pubitemid 37296536)
110. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001; 158: 1039-1051 (Pubitemid 32221796)
111. Burke AP, Tracy RP, Kolodgie F, Malcom GT, Zieske A, Kutys R, et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 2002; 105: 2019-2023 (Pubitemid 34465262)
112. Verma S, Devaraj S, Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 2006; 113: 2135-2150
113. Pepys MB, Hawkins PN, Kahan MC, Tennent GA, Gallimore JR, Graham D CA, et al. Proinflammatory effects of bacterial recombinant human C-reactive protein are caused by contamination with bacterial products, not by C-reactive protein itself. Circ Res 2005; 97: e97-e103.
114. Luc G, Bard JM, Juhan-Vague I, Ferrieres J, Evans A, Amouyel P, et al. C-reactive protein, interleukin-6, and fibrinogen as predictors of coronary heart disease: the PRIME Study. Arterioscler Thromb Vasc Biol 2003; 23: 1255-1261 (Pubitemid 36871282)
115. Mo VY, de Lemos JA. Individualizing therapy in acute coronary síndromes: using a múltiple biomarker approach for diagnosis, risk stratification, and guidance of therapy. Curr Cardiol Rep 2004; 6: 273-278
116. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350: 1387-1397 (Pubitemid 38419992)
117. Sánchez PL, Rodríguez MV, Villacorta E, Albarán C, Cruz I, Moreiras JM, et al. Kinetics of C-reactive protein release in different forms of acute coronary síndrome. Rev Esp Cardiol 2006; 59: 441-447 (Pubitemid 43949870)
118. Domínguez-Rodríguez A, García-Gonzalez M, Abreu-Gonzalez P, Ferrer J, Kaski JC. Relation of nocturnal melatonin levels to C-reactive protein concentration in patients with ST-segment elevation myocardial infarction. Am J Cardiol 2006; 26: 89-93. (Pubitemid 41828113)